Page 6 - தேசிய கொடுக்கப்படுவதுடன் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

June 3, 2021, 5:00 p.m. Eastern Daylight Time “We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.” In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer and hepatobiliary mal

United statesSan franciscoPatricia keeganJunshi bioscienceEli lillyMcdavid stilwellDenise powellJunshi biosciencesCoherus biosciencesInstitute of microbiology chinese academy scienceIr teamCoherus biosciences incDrug administrationGenentech incShanghai junshi biosciences co ltdExchange commission